

Special Issue

Penile Cancer and Rare Urogenital Malignancies: From Biology to Clinical Management

Message from the Guest Editors

Rare urogenital malignancies, such as penile cancer, upper tract urothelial carcinoma (UTUC), primary urethral carcinoma, and tumors of the penile skin or scrotum, present significant diagnostic and therapeutic challenges for clinicians. Their low prevalence has resulted in a scarcity of comprehensive data, which has impeded the establishment of standardized care protocols. This Special Issue will consolidate the current evidence on molecular biology, inflammation-driven mechanisms, microbial influences, and clinical outcomes. We invite the submission of original research, narrative or systematic reviews that address surgical management, systemic therapies, epidemiology, and prognostic biomarkers in this disease. By fostering interdisciplinary insights, we aim to enhance clinical decision-making and advance effective individualized treatment approaches in these uncommon but impactful genitourinary cancers.

Guest Editors

Dr. Mateusz Czajkowski

Department of Urology, Medical University of Gdańsk, Mariana Smoluchowskiego 17 Street, 80-214 Gdańsk, Poland

Prof. Dr. Marcin Matuszewski

Department of Urology, Medical University of Gdańsk, Mariana Smoluchowskiego 17 Street, 80-214 Gdańsk, Poland

Deadline for manuscript submissions

15 July 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/247609

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)